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Background: Congenital absence of the inferior vena cava (AIVC) is a rare malformation which may be associated
with an increased risk for deep vein thrombosis (DVT). However, the role of thrombophilia in AIVC and DVT is
unknown.
Methods: Between 1982 and 2013 41 patients (12 female, 29 male, mean age 28 S.D. 11 years) were detected at
the University of Düsseldorf, Germany, with AIVC. Based on medical history, clinical examination, imaging and
coagulation studies, we performed on this collective a risk characterisation. Extensive literature research added
further 123 published cases during 1993 and 2013. AIVC-patients were compared with iliocaval DVT-patients without
AIVC (n = 168) treated during the same period in our clinic (90 female, 78 male, mean age 38 S.D. 17 years).
Results: In contrast to classical DVT younger men were more often affected. Factor-V-Leiden-mutation,
5,10-methylenetetrahydrofolate reductase (MTHFR) polymorphism and hyperhomocysteinemia individually are
associated with an increased risk of DVT in patients with AIVC. Aplasia/hypoplasia of the right or left kidney is also
associated with IVCA.
Conclusions: AIVC should be considered in young patients who present with DVT involving the vena cava.
Analysis of publications with AIVC and our patients yielded a typical spectrum of AIVC-associated DVT
characteristics: AIVC occurs in young male adults, is revealed by proximal DVT, not necessarily accused by
precipitating factors like immobilisation, and is mostly located bilateral. Hereditary coagulation abnormalities seem
to be more often a contributing factor for DVT in AIVC.
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The formation of the inferior vena cava (IVC) in the hu-
man embryo is a complex process with fusion and regres-
sion of three paired veins which develop around the sixth
gestational week [1]. The posterior cardinal veins (PCV)
drain the venous flow from the medial and caudal portions
of the dorsal wall of the embryo into the venous sinus of
the primitive heart through Cuvier’s veins. On the other
hand, the omphalomesenteric veins, give rise to hepatic si-
nusoids, which lead directly to the coronary sinus via the
hepatocardiac ducts. The primitive kidney or mesoneph-
ros is drained by the ipsilateral subcardinal veins (SV),* Correspondence: drsagban@yahoo.de
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unless otherwise stated.which drain into the PCV. Between the two SV and the
omphalomesenteric system numerous anastomoses exist,
which give rise to the intrahepatic segment of the IVC. At
this stage the involution of the PCV and SV begins,
though the SV are only partially obliterated, maintaining
their distal portion, which gives rise to the corresponding
gonadal vein on the left and to the renal and postrenal
segments of the IVC on the right. At the same time as the
regression of the SV and PCV, a new system of SV de-
velops designed to drain the dorsal wall of the embryo.
These later veins develop later to the azygos and hemiazy-
gos venous systems.
Malformations of the IVC are unusual and include an
interruption of the IVC with azygos and hemiazygos vein
continuation [2,3]. 90% of those cases involve suprarenal de-
fects and only 6% involve the renal or infrarenal segments.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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extremely rare anomaly [4]. The reasons for such a develop-
mental failure are unclear. Most researchers believe that the
cause lies in embryonic dysgenesis affecting separate seg-
ments or the entire IVC [5-7]. Others suggest that AIVC is
not embryonic in origin, rather the result of intrauterine or
perinatal thrombosis [8,9].
Until now only case reports or small collectives were
reported for AIVC. Normally these malformations are
well collateralized because of their presence since em-
bryonic development. But some of them come to med-
ical attention because of deep vein thrombosis (DVT).
Although association with hyperhomcysteinemia [10]
and factor-V-Leiden have been reported [11], in litera-
ture described collectives are very small and partly con-
trary [13]. Only limited data is available on the role of
thrombophilia associated with AIVC [10-12]. To enlarge
the small cohort of our AIVC patients (n = 41), we per-
formed a Medline research reporting about cases with
AIVC and could identify 124 additional AIVC patients
with tested thrombophilia to ours (Additional file 1).
Methods
This study was approved by the local ethics committee
of the University Hospital of Düsseldorf, Germany and
informed consent was obtained from every single patient
treated and investigated in our department, which in-
cluded permission to use data from chart review and
genetic investigations for thrombophilc factors. The
study was performed in accordance with the Helsinki
Declaration.
Subjects
We studied 209 consecutive patients between January
1982 and June 2013 with a history of ileo-femoral DVT
with involvement of the vena cava. In this collective, 41
individuals with an AIVC were identified. Patients with
ilio-femoral, vena cava involving DVT without AIVC
(NoAIVC; n = 168) served as control group.
All patients were evaluated for determination of
thrombophilic and other abnormalities. In both, the pa-
tients with a history of DVT and/or patients with an
AIVC, blood samples were obtained after the diagnosis
of DVT or/and AIVC.
We compared and added our results with those reported
available on Medline database with sufficient relevant data.
References were identified through search of the Medline
database using the terms: “inferior vena cava”, “absence”,
“anomaly”, “agenesis” and “atresia”. 68 publications could
be identify, mostly case reports from 1993 until 2013, add-
ing information of 124 patients with AIVC to our collective
(Additional file 1). Publications without information about
patients’ thrombophilia were disclosed. The references
finally retained were chosen based on their relevance totopics addressed herein and to answer several questions im-
portant in clinical practice: demographic data of the AIVC
population, clinical DVT presentation, imaging for AIVC
diagnosis, additional anatomical anomalies, contribution of
thrombophilia screening and therapeutic approach.
All patients treated in our clinic, had an objectively di-
agnosed episode of DVT diagnosed by Doppler ultrason-
ography, computed tomography or magnetic resonance
imaging and/or by venography. These patients were
treated with anticoagulation or when feasible by surgery
in combination with anticoagulation [13].
Laboratory tests
All patients in our clinic were screened for inherited and ac-
quired defects in blood coagulation. We determined the ac-
tivities of lupus anticoagulant and hyperhomocysteinemia in
plasma, and performed a genetic analysis to determine
factor-V-Leiden-gene-mutation, the G20210A prothrombin-
gene-mutation, and the gene encoding C677T 5,10-methy-
lenetetrahydrofolate reductase (MTHFR)-mutation. Lupus
anticoagulant was measured with the DVV test and DVV
confirm test (American Diagnostica, Greenwich, Conn.).
Genetic analysis
DNA was extracted from peripheral-blood leukocytes
according to standard protocols with the use of the Che-
lex system (Bio-Rad, Munich, Germany). The presence
of factor-V-Leiden was determined by allele-specific
restriction-enzyme analysis [14]. For confirmation of the
genotypes, an oligonucleotide-ligation assay was per-
formed [15]. The results of the oligonucleotide-ligation
assay were in 100 percent concordance with the results
of genotypic analysis, as determined by an allele specific
restriction-enzyme assay. The G20210A prothrombin-
gene-mutation was identified by allele-specific restriction-
enzyme analysis [16]. Screening for the presence of the
C677T MTHFR-polymorphism was performed by the
method described by Frosst et al. [17].
Statistical analysis
The SPSS statistical package (SPSS for Windows, version
19.0 SPSS Inc., Chicago, IL., USA) was used for all statis-
tical analyses. Measure of variation is reported as stand-
ard deviation. Depending on the type of data, the
Wilcoxon rank-sum test, chi-square analysis, or Fisher’s
exact test (two-tailed) was used to assess the differences
between the groups. Multivariate analyses, including the
calculation of predictive values, were performed with the
use of a stepwise logistic-regression procedure.
Results
The characteristics of all patients are presented in
Table 1 (details of patients derived by literature research
is presented under Additional file 1).
Table 1 Characteristics of the patients with an aivc in this paper and in literature, compared with noaivc
Characteristics Patients with AIVC and
DVT in this paper (n = 41)
Patients with AIVC in
literature research (n = 124)
Patients with
NoAIVC (n = 168)
P Value of AIVC in this
paper and in literature
(n = 165) vs. NoAIVC (n = 168)
Sex male/female (male in %) 29/12 (70.7%)† 93/31 (75.0%)† 78/90 (46.4%) <0.0001
Mean age at appearance of
DVT (years ± SD) 28 ± 11.1† 28 ± 11.0† 38 ± 17.3 <0.0001
Range (min., max.) 16-58 8-67 8-84
preciptating factors for DVT -
No. (%) 25/41 (61.0%)† 52/122 (42.6%)†* 130/168 (77.4%) <0.0001
Left sided DVT (%) 4/41 (9.8%)† 26/124 (21.0%)† 83/168 (49.4%) <0.0001
Right sided DVT (%) 12/41 (29.3%)† 30/124 (24.2%)† 28/168 (16.7%) 0.049
Both sided DVT (%) 25/41 (61.0%)† 59/124 (47.6%)† 57/168 (33.9%) 0.002
DVT deep vein thrombosis. AIVC inferior vena cava agenesia. NoAIVC iliofemoral DVT with involvement of inferior vena cava without AIVC. SD standard deviance.
*in two cases not reported in literature.
†The difference between the AIVC groups was not significant.
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41 patients with AIVC could be identified at the Univer-
sity of Düsseldorf, Germany. Mean age was 28 ± 11.1 years
(min. 16, max. 58 years; 29 male and 12 female). Medline
database research revealed additional 124 AIVC patients
reported in 68 articles. Mean age here was 28.0 ± 11.0 years
(min. 8, max. 67 years; 93 male). Age difference and male
dominance in both groups was not statistical significant.
While in our department 36.6% of AIVC patients (15/41
patients) were surgical treated with a prosthetic bypass,
anticoagulation and compressing stockings [13], in litera-
ture only three reported bypasses could be identified
[9,18,19]. Thrombolysis was reported as treatment of first
choice in 14 patients [20-28]. Three publications implied
no information about their treatment, whereas the major-
ity of the published cases were treated conservatively with
anticoagulation and compressing stockings (n = 104/124).
DVT of the legs was present in all AIVC cases in our
clinic. A left sided DVT was evaluable in 9.8% (4/41 pa-
tients), right sided in 29.3% (12/41 patients). Both sided
affection was dominant with 61.0% in our AIVC patients
(25/41 patients). There was a trend toward a higher
prevalence of both sided DVT in our patients with AIVC
than among the AIVC patients in literature (prevalence,
61.0% vs. 47.6%; p = 0.10) but reached no significance.
In the here employed literature, left sided DVT could
be diagnosed in 21.0% (n = 26/124 patients), right sided
in 30/124 patients (24.2%). Both sided affections of DVT
was present in 59/124 patients (47.6%). Compared to
our AIVC-group, DVT pattern was not significant differ-
ent in literature.
Precipitating factors like immobilization, use of oral
contraceptives, etc. were more often documented in
NoAIVC (130/168) than in AIVC (77/163; 77.4% vs.
47.3%; p < 0.0001).NoAIVC
168 patients with NoAIVC served here as control group.
Mean age was 38.0 ± 17.3 years (min. 8, max. 84 years).
AIVC patients compared to NoAIVC patients were in
average 10 years younger (p < 0.0001). Male dominance
was also notable in AIVC (73.9% vs. 46.4%; p < 0.0001).
In NoAIVC, right sided DVT was seen in 16.7% vs.
25.4% in AIVC, both sided in 33.9% vs. 50.9% in AIVC.
Atypical site of DVT was significant for AIVC (right
sided: p = 0.049; both sided: p = 0.002), whereas left sided
DVT was more often observed in NoAIVC (49.4% vs.
18.3% in AIVC; p < 0.0001; Table 1).
Other organ anomalies in AIVC and NoAIVC
In many reported cases, AIVC was associated with other
anatomic disorders. The most recognized anomaly in
AIVC was aplasia of the right kidney (6.0% vs. 0% in
NoAIVC; p = 0.002), secondly, hypoplasia of the left kid-
ney in 2.7% of AIVC patients (vs. 0% in NoAIVC; p =
0.042). Polysplenia was just as well seen in 2.0% of AIVC
patients (vs. 0% in NoAIVC; p = 0.080; n.s.). May-
Thurner syndrome was only observed in five NoAIVC-
patients (3.0% vs. 0% in AIVC; p = 0.026). A preduodenal
portal vein was only observed in two cases of AIVC and
not statistical significant represented (p = 0.176; Table 2).
Prevalence of inherited risk factors
There was no significant difference in the prevalence of
factor-V-Leiden, prothrombin-gene-mutation, MTHFR-
gene-mutation, and hyperhomocysteinemia between the
41 AIVC patients in our clinic and the 124 AIVC pa-
tients derived from literature research. Homozygoty for
factor-V-Leiden or prothrombin-gene-mutation was not
detected. In AIVC, factor-V-Leiden-mutation was het-
erozygous in 27/165 patients and in 8/168 in NoAIVC.
Table 2 Prevalence of combined organ anomalies
Organ or system anomalies Patients with AIVC
in this paper (n = 41)
Patients with AIVC in
literature (n = 108/124;
16/124 NR†)
Patients with
NoAIVC (n = 168)
P Value of AIVC in this
paper and in literature
(n = 149) vs. NoAIVC (n = 168)
Hypoplasia/aplasia of left kidney (%) 1/41 (2.4%) 3/108 (2.8%) 0/168 (0.0%) 0.042
Hypoplasia/aplasia of right kidney (%) 2/41 (4.9%) 7/108 (6.5%) 0/168 (0.0%) 0.002
Polysplenia (%) 1/41 (2.4%) 2/108 (1.9%) 0/168 (0.0%) 0.080
Preduodenal portal vein (%) 1/41 (2.4%) 1/108 (0.9%)‡ 0/168 (0.0%) 0.176
May-Thurner syndrome (%) 0/41 (0.0%) 0/108 (0.0%) 5/168 (3.0%) 0.026
AIVC inferior vena cava agenesia. NoAIVC iliofemoral DVT with involvement of inferior vena cava without AIVC. NR not reported.
†In 16 of 124 reported cases in literature organ anomalies were not reported (NR); comparisons were calculated with 108 patients.
‡Absence of portal vein.
Sagban et al. Orphanet Journal of Rare Diseases  (2015) 10:3 Page 4 of 7Prothrombin-gene-mutation was heterozygous analysed
in 9/165 AIVC and in 3/168 NoAIVC patients. Except of
2/168 NoAIVC individuals, all MTHFR-mutations were
heterozygous (in AIVC 25/165; in NoAIVC 4/168). None
of the patients with a history of AIVC had both, factor-
V-Leiden and prothrombin-gene-mutation. A combin-
ation of two or more thrombophilic factors in-between
the groups showed no significant difference (Table 3).
A strong statistic trend was present for lupus anticoagu-
lant, detected in 6/165 AIVC patients vs. 1/168 in
NoAIVC (3.6% vs. 0.6%; p = 0.053), but reached no signifi-
cance (Table 3). Significant difference could be calculated
for prevalence of factor-V-Leiden and hyperhomocysteine-
mia between AIVC and NoAIVC patients (prevalence of
factor-V-Leiden, 16.4% vs. 4.8%; p = 0.001; prevalence of
hyperhomocysteinemia, 12.1% vs. 3.0%; p < 0.0001; Tables 3
and 4). The prevalence of prothrombin-gene-mutation
among the AIVC patients compared with NoAIVC pa-
tients was not significant (prevalence, 5.5% vs. 1.2%; p =
0.171; Table 4). By contrast, the MTHFR-gene-mutation
was predominantly associated with AIVC (prevalence,
12.7% vs. 3.6% in NoAIVC patients; p = 0.005; Table 4).
In a logistic-regression analysis in which adjustments were
made for age and gender (Table 5) and in which hyperho-
mocysteinemia, presence of factor-V-Leiden- polymorphism,
the prothrombin-gene-mutation, lupus anticoagulant andTable 3 Prevalence of hereditary coagulation defects
Patients with AIVC
this paper (n = 41)
Factor V Leiden (%) 11/41 (26.8%)
Prothrombin gene mutation (%) 1/41 (2.4%)
MTHFR gene mutation (%) 15/41 (36.6%)
Homocysteinemia (%) 15/41 (36.6%)
Lupus anticoagulant (%) 2/41 (4.9%)
Two thrombophilic factors positive (%) 9/41 (22.0%)
Three and more thrombophilic factors positive (%) 8/41 (19.5%)
AIVC inferior vena cava agenesia. NoAIVC iliofemoral DVT with involvement of infe
†One case homozygous for factor-V-Leiden-gene-mutation. ‡Two cases homozygouMTHFR-gene-mutation were included in the same model,
only the presence of factor-V-Leiden-gene-mutation, hyper-
homocysteinemia and MTHFR-gene-mutation could be
identified as independent risk factors (Table 5). Localisation
of DVT was also analysed. There was a statistical differ-
ence with regard to the prevalence or relative risk of both
or right sided DVT between AIVC and NoAIVC patients
(p = 0.049 resp. p = 0.002). Nevertheless, left sided DVT
was predominantly associated with NoAIVC than with
AIVC (prevalence, 18.2% among AIVC vs. 49.4% in
NoAIVC; p < 0.0001). Aplasia of the right and hypoplasia
of the left kidney were statistical significant in multivariate
analyses for AIVC (Table 5).
Discussion
The factors that predispose to venous thrombosis were ini-
tially described by Virchow in 1856 [29]. Individuals with
DVT usually have a predisposing risk factor, such as a gen-
etic abnormality causing hypercoagulability, pregnancy, etc.
AIVC should also be considered as a potential associated
anatomic abnormality, lacking of a main venous conduit,
which influences blood flow in the venous system [11]. Our
results showed that precipitating factors like immobilization
were less often an activator for DVT in AIVC patients.
Younger male with atypical DVT (right or both sided




NoAIVC (n = 168)
P Value of AIVC in
this paper and in
literature (n = 165)
vs. NoAIVC (n = 168)
16/124 (12.9%) 8/168 (4.8%)† 0.001
8/124 (6.5%) 2/168 (1.2%) 0.146
6/124 (4.8%) 6/168 (3.6%)‡ 0.005
5/124 (4.0%) 5/168 (3.0%) <0.0001
4/124 (3.2%) 1/168 (0.6%) 0.053
7/124 (5.6%) 4/168 (2.4%) 0.075
1/124 (0.8%) 3/168 (1.8%) 0.086
rior vena cava without AIVC.
s for MTHFR-gene-mutation.
Table 4 Prevalence of hereditary coagulation defects in













Gender (male) 46.4 73.9 <0.0001








Lupus anticoagulant 0.6 3.6 0.053
AIVC inferior vena cava agenesia. NoAIVC iliofemoral DVT with involvement of
inferior vena cava without AIVC.
*AIVC in this paper and in literature (n = 165).
†P values are for the univariate comparison between patients with NoAIVC and
those with AIVC.
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dence of risk factors. Thrombophilia plays also an import-
ant role in AIVC patients although other authors published
contrary findings based on case reports or small groups
[11,12]. While factor-V-Leiden-gene-mutation can be found
in a normal population roughly in 5%, a similar prevalence
could be shown in our control group (NoAIVC patients
4.8%). In AIVC the prevalence is more than three times
higher (16.4%). In our opinion this is not debted to a selec-
tion towards AIVC with DVT, because the here presentedTable 5 Relative risk of aivc associated with hereditary coagu
Risk factors in AIVC Univariate analysis
Relative risk (95% CI)
Age (years) 27.98 (35.65-41.17)
Gender (male) 3.274 (2.064-5.192)
Factor V Leiden 3.913 (1.721-8.895)
MTHFR gene mutation 3.354 (1.385-8.123)
Homocysteinemia 6.641 (2.243-19.659)
Aplasia of right kidney 58.4††
Hypoplasia of left kidney 36.1††
Right sided DVT 1.707 (0.999-2.918)
Both sided DVT 2.019 (1.298-3.141)
DVT deep vein thrombosis. AIVC inferior vena cava agenesia. MTHFR 5,10-methyle
*Univariate analyses were performed with the use of the chi-square test. Multivariat
cedure. CI denotes confidence interval.
**Univariate analyses were performed with the use of the T-test. Multivariate analys
CI denotes confidence interval.
†All stepwise logistic-regression analyses were performed with the following variabl
presence of the MTHFR-gene-mutation; hyperhomocysteinemia; presence of Lupus
polysplenia; right sided DVT; both sided DVT; age; gender; the P values indicate the
††Because no patient with NoAIVC had this combined defect, the estimated relative
these patients. For this reason, no confidence interval is given.prevalence of factor-V-Leiden-mutation in NoAIVC is simi-
lar to the normal population. In addition, homozygosis for
a common cytosine-to-thymidine mutation in the gene en-
coding MTHFR, C677T, is associated with high plasma
homocysteine concentrations and venous thrombosis.
There are conflicting results regarding the role of a homo-
zygous 677TT MTHFR genotype as a risk factor for venous
thromboembolism. Homozygosis for this polymorphism
was associated with high plasma homocysteine concentra-
tions and venous thrombosis in some studies [17,30,31] but
not in others [32]. In our study, the 677TT MTHFR-
genotype (homozygote) was only present in two cases of
NoAIVC. All other MTHFR-positive testing’s were hetero-
zygous with the 677CT MTHFR genotype combined with
hyperhomocysteinemia. In our opinion this genotype in
combination with metabolic anomaly has an influence on
the risk of DVT; the prevalence of the 677CT MTHFR-
genotype in AIVC was higher than in the group of
NoAIVC. Like factor-V-Leiden, MTHFR-gene-mutation
was predominant in AIVC, mostly in combination with hy-
perhomocysteinemia. The G20210A prothrombin-gene-
mutation or the presence of lupus anticoagulant seems to
play no role here.
We confirmed the importance of factor-V-Leiden as a risk
factor for venous thromboembolism in AIVC. In addition, we
found that factor-V-Leiden is a risk factor that is independent
of other known determinants of thrombosis; specifically, it
is independent of the G20210A prothrombin or MTHFR-
gene-mutation, whereas MTHFR-mutation in combination
with hyperhomocysteinemia is independently from factor-
V-Leiden-mutation also a risk factor for DVT in AIVC.lation defects and anatomic malformations
Multivariate analysis†
P value Relative risk (95% CI) P value
<0.0001** 22.31 (32.62-39.89) <0.0001
<0.0001* 5.789 (3.131-10.701) <0.0001
0.001* 4.890 (1.647-7.517) <0.0001
0.005* 2.132 (1.016-7.072) 0.005
<0.0001* 6.916 (2.544-19.814) <0.0001
0.002* 64.8†† 0.002
0.059* 46.7†† 0.042
0.049* 1.663 (1.025-3.267) 0.049
0.002* 2.003 (1.305-3.349) 0.002
netetrahydrofolate reductase.
e analyses were performed with the use of the stepwise logistic-regression pro-
es were performed with the use of the stepwise logistic-regression procedure.
es: presence of factor-V-Leiden; presence of prothrombin-gene-mutation;
anticoagulant; aplasia of the right kidney; hypoplasia of the left kidney;
significance of each risk factor independently.
risk was calculated on the basis of the probability of a combined defect in
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caused by embryonic dysgenesis or by an intrauterine in-
sult during the perinatal period [6,33]. AIVC have been
associated with other congenital anomalies, like renal hy-
poplasia/agenesis. This anatomic anomaly for the right
kidney was found in our research in 6% of AIVC, but not
in NoAIVC patients. The right renal hypoplasia is suggest-
ive of a defect in the formation of the IVC in these seg-
ments, since the embryologic right SV does not drain
the mesonephros [34]. A hypoplastic left kidney was also
found here in AIVC (2.7%). However, it is not clear
whether this represents a true congenital malformation or
atrophy of a previously normal kidney due to long-
standing poor perfusion or thrombosis secondary to vascu-
lar malformation. The question of hereditary is not clearly
answerable, but two cases in our collective direct to this
hypothesis. In one case, the son of a patient with AIVC
was diagnosed with DVT bilateral. Computed tomography
showed here also an AIVC in the same segment like his
father. The second remarkable case was the asymptomatic
twin-brother of an AIVC patient, who received imaging for
other reasons. His AIVC pattern was identical to his twin
brother. The thrombophilic patterns were identical in-
between the relatives. Of course, these relatives with AIVC
cannot be representative, but both give rise to a hereditary
hypothesis of AIVC. Interestingly, factor-V-deficiency is
caused by mutations in the F5 gene, located on the long
(q) arm of chromosome 1 at position 23, nearby LEFTY2
(Left-Right Determination Factor 2), playing a role in left-
right asymmetry determination of organ systems during
development at cytogenetic location 1q42.1 [35]. Renal
dysgenesis and MTHFR-mutation is also located on this
chromosome [35]. Further genetic investigations could
here emblaze the hereditary genesis of AIVC.
Conclusions
This study shows that AIVC is associated with a higher
prevalence of thrombophilia even compared to patients
with iliofemoral DVT with involvement of inferior vena
cava but without AIVC. AIVC should be considered in
young patients who present with DVT involving the vena
cava. Analysis of publications with AIVC and our patients
yielded a typical spectrum of AIVC-associated DVT char-
acteristics: AIVC occurs in young male adults, is revealed
by proximal DVT, not necessarily accused by precipitating
factors like immobilisation, and is mostly located bilateral.
Hereditary coagulation abnormalities seem to be more
often a contributing factor for DVT in AIVC.Additional file
Additional file 1: AIVC reported in literature and employed here in
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